- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept (MK-7962) Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care
This study is looking at a new medicine called sotatercept for people with pulmonary arterial hypertension (PAH). Researchers want to see how the body handles the medicine and check for any side effects. It’s a randomised study, meaning some people will get different doses.
For: Pulmonary Arterial Hypertension (PAH)Czechia · Poland · Spain - RecruitingPHASE2
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
This study looks at a new medicine called sotatercept for a specific type of high blood pressure in the lungs (Cpc-PH) linked to heart failure. It's for people who were in a previous study to see how the medicine works long-term and if it's safe.
For: Hypertension, PulmonaryUnited States · Belgium · Canada - RecruitingPHASE2
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
This study is looking at a new medicine called sotatercept for children aged 1 to 17 with a serious lung condition called pulmonary arterial hypertension (PAH). We want to see if it's safe and how the body handles it over 24 weeks, alongside their usual PAH treatments.
For: Pulmonary Arterial HypertensionUnited States · Australia · Colombia - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
For: Pulmonary Arterial HypertensionUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo_Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality
This study is testing a new medicine, sotatercept, for adults with severe pulmonary arterial hypertension (PAH). Researchers want to see if adding sotatercept to existing treatments can prolong life, prevent lung transplants, or reduce hospital stays related to PAH worsening.
For: Pulmonary Arterial Hypertension (PAH)Belgium · Netherlands · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)
This study is testing a new medicine, sotatercept, for a type of high blood pressure in the lungs called Cpc-PH, which is linked to a specific kind of heart failure (HFpEF). Researchers want to see if the medicine can improve lung pressure over 24 weeks compared to a dummy treatment.
For: Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)Belgium · Germany · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
This study is looking at a new medicine, sotatercept, for people recently diagnosed with a serious lung condition called Pulmonary Arterial Hypertension (PAH). It compares sotatercept to a dummy medicine to see if it improves well-being and reduces serious health events when added to standard treatments.
For: Therapeutic confirmatory (phase III)Spain · Poland · France - Active not recruitingPHASE2
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
This study is looking into a new treatment called sotatercept for pulmonary arterial hypertension (PAH). It's an extension of a previous study. The main aim is to see if sotatercept, given in doses based on weight groups, is safe and can be tolerated by people with PAH over a longer time.
For: Pulmonary Arterial HypertensionUnited States · Argentina · Australia